UBS analyst Dan Leonard raised the firm’s price target on Guardant Health (GH) to $110 from $80 and keeps a Buy rating on the shares. With another beat and raise, UBS sees multiple catalysts ahead for Guardant Health, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $100 from $65 at Citi
- Guardant Health price target raised to $100 from $80 at BTIG
- Guardant Health price target raised to $100 from $75 at Mizuho
- Guardant Health price target raised to $85 from $70 at Barclays
- Guardant Health price target raised to $100 from $75 at Canaccord